![{ Bio Portrait }](assets/images/583_bioprofile.jpeg)
Ian Swan is an associate in Axinn’s intellectual property group. His practice focuses on pharmaceutical and biotechnology-related patent litigation.
Ian earned his JD from Boston College Law School. While in law school, he interned at the Essex County District Attorney's Office and also interned for the United States District Court for the District of Massachusetts.
Ian was a summer associate with Axinn in 2022 and holds a BS in Biology from the University of Massachusetts, Amherst.
*Not yet admitted to the Washington, DC Bar.
Thought Leadership
- Hatch-Waxman Overview, Bloomberg Law, June 13, 2024
- Del. IP Ruling May Mark Limitation-By-Limitation Analysis Shift, Law360, May 16, 2024
- Potential Shifts in Section 337 Precedent: What The Data Tells Us, IPWatchdog, May 13, 2024
- Chevron Deference on the Brink: Small Fish May Mean Big Changes for FDA, FDLI’s Update Magazine, Spring 2024 Issue, March 29, 2024
- FDA After Chevron, Axinn IP Update, March 5, 2024
- FDA’s Califf is ‘Very Worried’ About Judges Overruling Agency Decisions, Pink Sheet, January 25, 2024
Education
- JD – Boston College Law School (2023)
- BS, Biology – University of Massachusetts, Amherst (2019)
Admissions
- Maryland